nivolumab,ipilimumab
bms
[]
 nivo + ctx or ipi vs ctx as 1l for escc
@ asco-gi 2023 29-mo follow-up checkmate 648 mos pdl1 &gt;1%: 15 vs 13.1 vs 9.1 mpfs pdl1 &gt;1%: 6.8 vs 4.0 vs 4.4 dor &gt;24 mo: 22%, 36%, 13 continuous value of both io therapies 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine